Romiplostim
- Generic Name
- Romiplostim
- Brand Names
- Nplate
- Drug Type
- Biotech
- CAS Number
- 267639-76-9
- Unique Ingredient Identifier
- GN5XU2DXKV
- Background
Romiplostim is a thrombopoiesis stimulating dimer Fc-peptide fusion protein (peptibody) to increase platelet production through activation of the thrombopoietin receptor. The peptibody molecule has two identical single-chain subunits, each one is made up of 269 amino acid residues. Each subunit consists of an IgG1 Fc carrier domain that is covalently attached to a polypeptide sequence that contains two binding domains to interact with thrombopoietin receptor c-Mpl. Each domain consists of 14 amino acids. Interestingly, romiplostim's amino acid sequence is not similar to that of endogenous thrombopoietin. Romiplostim is produced by recombinant DNA technology in Escherichia coli. FDA approved on August 22, 2008.
- Indication
Treatment of chronic immune thrombocytopenic purpura.
- Associated Conditions
- Chronic immune thrombocytopenia, Refractory immune thrombocytopenia
Patients With Relapsed Ovarian Cancer (2nd and 3rd Line) Treated With Chemotherapy According to AGO Guidelines
- Conditions
- Ovarian Cancer
- Interventions
- First Posted Date
- 2018-08-09
- Last Posted Date
- 2021-02-08
- Lead Sponsor
- Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
- Target Recruit Count
- 21
- Registration Number
- NCT03622931
- Locations
- 🇩🇪
Praxisklinik für Krebsheilkunde für Frauen Drs. Kittel /Klare / Wetzel, Berlin, Germany
🇩🇪Charité Campus Virchow-Klinikum Universitätsmedizin Berlin, Berlin, Germany
🇩🇪Ev. Waldkrankenhaus Spandau, Berlin, Germany
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
- Conditions
- Chemotherapy-induced Thrombocytopenia
- Interventions
- Other: Placebo
- First Posted Date
- 2017-12-05
- Last Posted Date
- 2025-01-20
- Lead Sponsor
- Amgen
- Target Recruit Count
- 165
- Registration Number
- NCT03362177
- Locations
- 🇵🇹
Centro Hospitalar Universitario de Sao Joao, EPE - Hospital Sao Joao, Porto, Portugal
🇷🇺Autonomic SHI Republican clinical oncology dispensary of MoH of the Republic of Tatarstan, Kazan, Russian Federation
🇷🇺Clinical hospital 2, Group of companies medsi, Moscow, Russian Federation
Evaluating the Pharmacokinetics and Pharmacodynamics of Romiplostim in Patients With Immune Thrombocytopenia (ITP)
- First Posted Date
- 2016-08-16
- Last Posted Date
- 2024-04-29
- Lead Sponsor
- Kyowa Kirin China Pharmaceutical Co., Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT02868060
- Locations
- 🇨🇳
Wuxi People's Hospital, Wuxi, China
🇨🇳Peking Union hospital, Beijing, China
🇨🇳West China hospital, Chengdu, China
Efficacy and Safety of Romiplostim in Adult Subjects With Persistent or Chronic Immune Thrombocytopenia (ITP)
- First Posted Date
- 2016-08-16
- Last Posted Date
- 2024-04-29
- Lead Sponsor
- Kyowa Kirin China Pharmaceutical Co., Ltd.
- Target Recruit Count
- 203
- Registration Number
- NCT02868099
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, China
Immunomodulation With Romiplostim in Young Adults With ITP
- First Posted Date
- 2016-05-03
- Last Posted Date
- 2020-05-07
- Lead Sponsor
- University Hospital, Basel, Switzerland
- Target Recruit Count
- 15
- Registration Number
- NCT02760251
- Locations
- 🇨🇭
Lucerne Cantonal Hospital, Lucerne, Lucern, Switzerland
🇨🇭Aarau Cantonal Hospital, Aarau, Switzerland
🇨🇭Liestal Cantonal Hospital, Liestal, Basel-Land, Switzerland
An Observational Study to Evaluate the Efficacy of Biweekly Romiplostim in Adult Patients With ITP
- First Posted Date
- 2015-01-14
- Last Posted Date
- 2015-01-14
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 20
- Registration Number
- NCT02338414
Long-term Study of Romiplostim in Thrombocytopenic Pediatric Patients With Immune Thrombocytopenia (ITP)
- First Posted Date
- 2014-10-30
- Last Posted Date
- 2022-06-23
- Lead Sponsor
- Amgen
- Target Recruit Count
- 203
- Registration Number
- NCT02279173
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
Prevention of Thrombocytopenia in Glioblastoma Patients
- First Posted Date
- 2014-08-28
- Last Posted Date
- 2018-04-25
- Lead Sponsor
- University Hospital, Lille
- Target Recruit Count
- 20
- Registration Number
- NCT02227576
- Locations
- 🇫🇷
AP-HM,Hôpital La Timone, AP-HM, Marseille, Marseille, France
🇫🇷Hôpital Neurologique Pierre Wertheimer, Lyon,, Lyon, France
🇫🇷AH-HP, Hôpital Pitié-Salpêtrière, Service de Neurologie 2, Paris, France
A Phase 2 Study to Evaluate the Efficacy and Safety of AMG531 in Aplastic Anemia
- First Posted Date
- 2014-03-21
- Last Posted Date
- 2024-04-30
- Lead Sponsor
- Kyowa Kirin Korea Co., Ltd.
- Target Recruit Count
- 35
- Registration Number
- NCT02094417
- Locations
- 🇰🇷
Korea, Republic of, Seoul, Korea, Republic of
Study of Romiplostim for Chemotherapy Induced Thrombocytopenia
- Conditions
- Isolated Chemotherapy-induced Thrombocytopenia
- Interventions
- First Posted Date
- 2014-02-03
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT02052882
- Locations
- 🇺🇸
Memorial Sloan Kettering at Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.